NCT05238961

Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical imaging substudy will use the small molecule translocator protein (TSPO) ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron Lazar (IRB-300007806). The positron emission tomography (PET) tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

Conditions

• Critical Asymptomatic Carotid Artery Disease
• Non-Critical Asymptomatic Carotid Artery Disease

Interventions

Type	Name	Description
DRUG	[18F]DPA-714	Investigational PET Tracer \[18F\]DPA-714

Timeline

• Start date: 2028-04-01
• Primary completion: 2028-04-01
• Completion: 2028-04-01
• First posted: 2022-02-14
• Last updated: 2026-02-20

Regulatory

• FDA-regulated drug study